This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, R. N.
Right arrow Articles by Sader, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, R. N.
Right arrow Articles by Sader, H. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2008, p. 3763-3775, Vol. 52, No. 10
0066-4804/08/$08.00+0     doi:10.1128/AAC.00294-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Antimicrobial Activity of DC-159a, a New Fluoroquinolone, against 1,149 Recently Collected Clinical Isolates{triangledown}

Ronald N. Jones,1,2* Thomas R. Fritsche,1 and Helio S. Sader1,3

JMI Laboratories, North Liberty, Iowa,1 Tufts University School of Medicine, Boston, Massachusetts,2 Universidade Federal de Sao Paulo, Sao Paulo, Brazil3

Received 3 March 2008/ Returned for modification 30 March 2008/ Accepted 15 June 2008

The activity of DC-159a, a novel orally administered fluorinated quinolone, was evaluated by reference broth microdilution or agar dilution methods against 1,149 recently collected clinical isolates from five continents. Against pathogens associated with community-acquired respiratory tract infections (CA-RTIs), the MIC90s were 0.12 µg/ml for Streptococcus pneumoniae, 0.015 to 0.03 µg/ml for Haemophilus influenzae, 0.03 µg/ml for Moraxella catarrhalis, and 0.12 µg/ml for beta-hemolytic streptococci. Similarly, DC-159a was potent against various types of staphylococci (MIC90 range, 0.03 to 2 µg/ml), Enterococcus faecalis (MIC90, 4 µg/ml), wild-type isolates of the family Enterobacteriaceae (MIC90 range, 0.06 to 2 µg/ml), wild-type Pseudomonas aeruginosa (MIC90, 2 µg/ml), and Acinetobacter spp. (MIC90, 0.12 µg/ml). Fluoroquinolone-nonsusceptible organism subsets usually had elevated DC-159a MICs, but the MICs were often two- to fourfold lower than those of levofloxacin and moxifloxacin. In conclusion, DC-159a appears to possess a balanced broad spectrum of activity that exceeds the activities of the currently marketed fluoroquinolones, especially against pathogens that cause CA-RTIs.

* Corresponding author. Mailing address: JMI Laboratories, 345 Beaver Kreek Center, Suite A, North Liberty IA 52317. Phone: (319) 665-3370. Fax: (319) 655-3371. E-mail: ronald-jones{at}jmilabs.com

{triangledown} Published ahead of print on 23 June 2008.

Antimicrobial Agents and Chemotherapy, October 2008, p. 3763-3775, Vol. 52, No. 10
0066-4804/08/$08.00+0     doi:10.1128/AAC.00294-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»